IVI RMA Global, a leading fertility care organization, and Conceivable Life Sciences have announced a strategic partnership – including an investment by IVI RMA in Conceivable – to introduce AURA, a robotic IVF laboratory platform, to a U.S. clinic in 2027, with expansion planned across IVI RMA’s network in Europe, Latin America, and the Middle East.
AURA is designed to work alongside embryologists rather than replace them, helping perform hundreds of manual, operator-dependent steps with machine precision. The system perceives, reasons, and executes inside a live clinical environment. In ongoing pilot studies, over 100 patients have been treated, more than 1,000 eggs processed, and live births achieved.
The partnership addresses a fundamental variability problem in IVF. Outcomes can differ significantly between labs and operators, even within the same clinic. AURA aims to standardize the laboratory environment where embryo quality is determined, reducing that variability.
“Every patient who walks through the door of an IVF clinic deserves the same quality of care, regardless of which lab they are in or which country they are in,” said Conceivable co-founder Dr. Alejandro Chavez Badiola. “That has never been consistently possible before.”
“By integrating innovative platforms such as AURA into our laboratory ecosystem, we are not only improving our patients’ abilities to build families, but also demonstrating how advanced technology can complement the expertise of embryologists and clinicians,” said IVI RMA executive chairman Prof. Antonio Pellicer, who will also join Conceivable’s board.
